Syndax Pharmaceuticals, Inc. SNDX
Set alert
13.10 USD -0.55 -4.03%
At close · Nov 2
13.08 -0.02 -0.15%
After hours · Nov 2, 5:49 PM ET
12.90 Day range 13.75
12.80 52-week range 25.59
- YTD
- -37.65%
- 1 year
- -4.38%
- Open
- 13.62
- Prev close
- 13.65
- Mkt cap
- 1.16B
- Vol
- 3.18M
- Avg vol
- 1.96M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.90
- High
- 13.75
- Forward P/E
- -17.89
- Beta
- 0.45
- Short ratio
- 8.03
- Inst. own
- 126.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 17.18
- 200-d avg
- 20.23
- 1y target
- 37.27
1D chart
Events in this range
- Nov 2, 2026Earnings: —; estimate -0.4928; surprise —%
Signals (57)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 3:49 PM | 7 hours ago |
| SMA: Bullish | 3:46 PM | 7 hours ago |
| SMA: Bullish | 3:45 PM | 7 hours ago |
| MACD: Buy Signal | 3:42 PM | 7 hours ago |
| RSI: Oversold | 3:32 PM | 7 hours ago |
| SMA: Bearish | 3:17 PM | 8 hours ago |
| SMA: Bullish | 3:16 PM | 8 hours ago |
| SMA: Bearish | 3:13 PM | 8 hours ago |
| MACD: Sell Signal | 3:05 PM | 8 hours ago |
| MACD: Buy Signal | 3:03 PM | 8 hours ago |
| MACD: Sell Signal | 3:02 PM | 8 hours ago |
| MACD: Buy Signal | 2:50 PM | 8 hours ago |
| MACD: Sell Signal | 2:49 PM | 8 hours ago |
| MACD: Buy Signal | 2:48 PM | 8 hours ago |
| MACD: Sell Signal | 2:47 PM | 8 hours ago |
| MACD: Buy Signal | 2:28 PM | 9 hours ago |
| RSI: Overbought | 2:28 PM | 9 hours ago |
| SMA: Bullish | 2:27 PM | 9 hours ago |
| MACD: Sell Signal | 2:20 PM | 9 hours ago |
| SMA: Bearish | 2:15 PM | 9 hours ago |
Newest 20 of 57.
Key statistics
- Market cap
- 1.17B
- Enterprise value
- 1.25B
- Trailing P/E
- 0.00
- Forward P/E
- -17.89
- PEG ratio
- 0.00
- Price / sales
- 4.64
- Price / book
- 77.51
- EPS (TTM)
- -2.52
- Beta
- 0.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -87.52%
- Revenue (TTM)
- 252.25M
- Revenue growth
- 91.80%
- Free cash flow
- -150.08M
- Total cash
- 554.27M
- Total debt
- 589.38M
- Return on equity
- -255.93%
- Shares outstanding
- 89.30M
- Short % of float
- 20.51%
- 50-day average
- 17.18
- 200-day average
- 20.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 37.27 +184.5% upside
Now 13.10
- Target (low)
- 23.00
- Target (mean)
- 37.27
- Target (high)
- 57.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy2
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -0.48378.
Financials — quick view
SNDX Revenue — quarterly 72.79M
SNDX Net income — quarterly -49.36M
SNDX EPS — quarterly -0.55
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.4928 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.44767 | -0.55 | -0.10 | -22.86% |
| Apr 30, 2026 | Mar 31, 2026 | -0.59 | -0.48 | +0.11 | +18.64% |
| Feb 26, 2026 | Dec 31, 2025 | -0.58404 | -0.78 | -0.20 | -33.55% |
| Nov 3, 2025 | Sep 30, 2025 | -0.74 | -0.70 | +0.04 | +5.41% |
| Aug 4, 2025 | Jun 30, 2025 | -1.00 | -0.83 | +0.17 | +17.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2026 | UBS | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syndax.com
News
- Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript
- What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
- Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
- Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate
- Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
- Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
- Critical Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Regeneron Pharmaceuticals (NASDAQ:REGN)
- Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- Syndax Announces Participation in November Investor Conferences
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
Your note
Sign in to keep a note on SNDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOTWOOD NICHOLAS A.J. | Officer | Sale | Jun 11, 2026 | 60,885 |
| GALLAGHER NEIL | Officer | Sale | Feb 9, 2025 | 85,095 |
| GOLDAN KEITH ALAN | Chief Financial Officer | Sale | May 31, 2026 | 139,252 |
| HUBER MARTIN H JR | Director | Stock Award(Grant) | Feb 3, 2026 | 103,000 |
| JARRETT A JENNIFER | Director | Stock Award(Grant) | Feb 3, 2026 | 114,000 |
| KATKIN KEITH A | Director | Stock Award(Grant) | Feb 3, 2026 | 124,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.18% | 9,020,006 | 118.16M | Jun 29, 2026 |
| Kynam Capital Management, LP | 9.09% | 8,050,959 | 105.47M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.61% | 5,861,265 | 76.78M | Jun 29, 2026 |
| State Street Corporation | 6.39% | 5,658,424 | 74.13M | Jun 29, 2026 |
| Bank of America Corporation | 4.57% | 4,045,094 | 52.99M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.43% | 3,927,892 | 51.46M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 2,823,912 | 36.99M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.87% | 2,547,266 | 33.37M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,296,035 | 30.08M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.37% | 1,211,108 | 15.87M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 1,013,559 | 13.28M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.10% | 971,932 | 12.73M | Jul 30, 2026 |